Sarah Hogan

Barts Health NHS Trust — United Kingdom

Neuroscience · Life Sciences

21h-index1.3kcitations59works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hearing Loss and Rehabilitation(14), Hearing, Cochlea, Tinnitus, Genetics(7), Ear Surgery and Otitis Media(7), Nonmelanoma Skin Cancer Studies(7), Family and Disability Support Research(5)

Publications59 total

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant
Blood·2025Open Access
BI11 Squamoid eccrine ductal carcinoma: a case series of an aggressive skin cancer occurring almost exclusively in immunocompromised patients
British Journal of Dermatology·2025Open Access
BI09 The OCTOPUS study (Optical Coherence Tomography in OutPatient dermatology UnitS): can noninvasive imaging improve diagnosis of keratinocyte (pre)cancers in immunosuppressed and immunocompetent patients?
British Journal of Dermatology·2025Open Access
From Bytes to Bites; Advancing Data Collection Methodologies for Enhanced Branded Food Insights
Proceedings of The Nutrition Society·2024Open Access
O11 Associations between hyperlinearity of the sole and filaggrin variants in atopic eczema in a South Asian population: a cross-sectional study
British Journal of Dermatology·2024Open Access
A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).
Journal of Clinical Oncology·2024· 17 cited
Repair of Endothelial Glycocalyx Improves Lung Function During Human Ex Vivo Lung Perfusion
The Journal of Heart and Lung Transplantation·2024Open Access
Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial
Blood·2023· 3 cited
CTIM-37. A PILOT STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL AND SCNSL)
Neuro-Oncology·2023Open Access
P-004 Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD+, newly diagnosed multiple myeloma patients
Clinical Lymphoma Myeloma & Leukemia·2023
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
Journal of the European Academy of Dermatology and Venereology·2023· 18 citedOpen Access
Deep palmar phenotyping in atopic eczema: patterns associated with <i>filaggrin</i> variants, disease severity and barrier function in a South Asian population
British Journal of Dermatology·2023· 9 citedOpen Access
A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
Blood·2022· 21 cited
Modelling domestic marine and coastal tourism demand using logit and travel cost count models
Economic Analysis and Policy·2022· 13 cited
Suicide and Suicidality in Children and Adolescents with Chronic Skin Disorders: A Systematic Review
Acta Dermato Venereologica·2022· 23 citedOpen Access
Response to ‘The role of curettage as an intervention for basal cell carcinoma’. Re. ‘Interventions for basal cell carcinoma: abridged Cochrane systematic review and <scp>GRADE</scp> assessments’: reply from the authors
British Journal of Dermatology·2021Open Access
Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood·2021· 3 cited
International Telepractice for Therapy and Training: Auditory Verbal UK's Perspective
Perspectives of the ASHA Special Interest Groups·2021
179 Phenotype association with Filaggrin loss of function from the Tower Hamlets Eczema Assessment (THEA)
Journal of Investigative Dermatology·2021· 1 cited
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Discovery Research Portal (University of Dundee)·2021· 23 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

David R. Moore(9), Jason Thomson(5), Catherine Harwood(4), Simon Stephens(4), R. Meredith(4), Douglas E. H. Hartley(3), D. E. Callaghan(3), A Rayment(3), Jacqueline Stokes(3), Oliver Kacelnik(3), Carl H. Parsons(3), Bjorn Thomas(3), Xiang Li Tan(3), Sasha Dhoat(3), Rubina Begum(3), Habiba Khanam(3), David P. Kelsell(3), Edel A. O’Toole(3), Charlotte M. Proby(2), Beverly A. Wright(2)